Opaganib is a Sphingosine-kinase (SK)-2 inhibitor with anti-inflammatory and anti-viral properties. Five severe COVID-19 patients were treated with opaganib on compassionate-use basis. Treatment was well tolerated and associated with faster lymphocyte count increase and improved oxygenation. Opaganib efficacy for COVID-19 should be examined in a clinical trial setting.
No takes yet. Share an insight, caveat, or question.
Kurd et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: